SAN DIEGO, May 23, 2012 /PRNewswire/ -- ResMed Inc. (NYSE:RMD) today announced the launch of the first product in Japan using technology from its recently acquired company, BiancaMed. The product, launched by BiancaMed partner Omron Healthcare, is a new wireless sleep monitoring device. The Omron Sleep Design HSL-101 is part of a new strategy by Omron, named "All for Healthcare."
How Omron Sleep Design WorksThe device uses ResMed technology to offer wireless, non-contact sleep monitoring which in turn connects to health care support services in Japan. To use the Omron Sleep Design HSL-101, a patient places the device beside the bed. With ResMed's non-contact sensing technology, the device measures sleep throughout the night and can report key sleep quality metrics, such as sleep onset time and total sleep time. In the morning, users can generate a full report on the night's sleep with the push of a button. When the data is connected to the cloud as part of Omron's Wellness Link service, a full picture of sleep health is provided, alongside a customized summary of health tips and advice. ResMed and BiancaMed ResMed is a leading developer, manufacturer and distributor of systems to diagnose, treat and manage sleep-disordered breathing, a serious health condition in which people experience breathing issues during sleep ranging from simple snoring to periods of completely obstructed breathing, known as sleep apnea. As such, ResMed recognizes that sleep monitoring represents a huge market opportunity globally, part of an increasing recognition of the impact of disturbed sleep on numerous important health issues, including heart disease, stroke, type 2 diabetes and more, as well as an increasing trend toward proactive, preventative health care models. The need for convenient, cost-effective screening and monitoring solutions continues to grow as economic pressures are causing governments and insurance providers worldwide to focus on cost savings and therapeutic efficacy in both the diagnosis and treatment of health disorders. ResMed's acquisition of BiancaMed in 2011 serves this need two-fold: by providing a simple screening solution, and by providing novel alternatives for monitoring across multiple disease categories, such as heart failure, diabetes and more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts